A bill to require regulatory review of pharmaceutical products from Chinese entities, and for other purposes.

Summary

No official summary available for this bill.

Full Text

Legislative Actions

1. 2026-04-16

   Introduced in Senate

2. 2026-04-16

   Read twice and referred to the Committee on Health, Education, Labor, and Pensions.